EISSN 2667-4440

INDEXED IN: China National Knowledge Infrastructure (CNKI) TURK J NEPHROL IS INDEXED IN WEB OF SCIENCE AND SCOPUS

Turkish Journal of Nephrology

34 443 2025

MOST CITED ARTICLES

Kidney Health for Everyone Everywhere - from Prevention to Detection and Equitable Access to Care

Li et al.

Acute Kidney Injury in SARS-CoV-2 Infected Critically III Patients

Gündoğan et al.

Proteolytic Activation of the Epithelial Sodium Channel in Nephrotic Syndrome by Proteasuria: Concept and Therapeutic Potential

Artunc, Ferruh

Clinical Features and Outcomes of Patients with Granulomatosis with Polyangiitis and Review of Literature

Arslan et al.

Coronavirus Disease 2019 Infection and Nursing in Patients Undergoing Hemodialysis Treatment

Demirağ and Hintistan.

Serum Total Sialic Acid and Lipid-linked Sialic Acid May Be the New Potential Biomarkers in Paracetamol Nephrotoxicity

Öksüz et al.

Prevalence and Characteristics of Atrial Fibrillation in Turkish Patients Undergoing Hemodialysis

Hasbal et al.

The Turkish Society of Nephrology from 1970 to 2020: A 50-Year History

Kenan Ateş

Evaluation of Long-Term Thirst due to Ramadan Fasting in Terms of Acute Kidney Injury

Baloğlu et al.

Examination of the Effects of Nursing Interventions on Intradialytic Hypotension

Kesik and Özdemir.

POPULAR ARTICLES

Burden, Access, and Disparities in Kidney Disease

Crews et al.

A New Beginning with a New Name

Bülent Tokgöz

More

Letter to the Editors

Hepatotoxicity in Patients with Autosomal Dominant Polycystic Kidney Disease Other Than Using Tolvaptan

Nazife Nur Ozer Sensoy ¹ , Ozkan Gungor ²

Author Affiliation(s)

1.

Department of Nephrology, Bursa City Hospital, Bursa, Türkiye

2.

Department of Nephrology, Kahramanmaras Sütcü Imam University School of Medicine, Kahramanmaraş, Türkiye

Turkish J Nephrol 2025; 34: 231-232

DOI: 10.5152/turkjnephrol.2025.251000

Read: 18 Downloads: 15 Published: 01 July 2025

Volume 34, Issue 3, July 2025

Previous Article

Cite this article as: Sensoy, NNO, Gungor O. Hepatotoxicity in patients with autosomal dominant polycystic kidney disease other than using tolvaptan. Turk J Nephrol. 2025;34(3):231-232.

Files